DMA Diamedica Therapeutics

DiaMedica Inc. (TSX VENTURE:DMA) is pleased to announce the presentation of new
compelling Type 2 diabetes data from studies of DM-204 at the Windhover
Therapeutic Area Partnership Conference in Boston, MA, USA. 


In an independently conducted study, chronic administration of DM-204 prevented
disease progression within an in vivo Type 2 diabetes model. Treatment with
DM-204 resulted in statistically significant lower mean differences compared to
untreated animals after 21 days for the following parameters:




--  2.6% (p=0.0103) lower HbA1c levels at day 21  
--  70% (p=0.0058) lower difference in fasting blood glucose levels 
--  25 mm/Hg (p=0.0004) lower difference in systolic blood pressure levels 
-- greater than 20% (p=0.0156) improvement in total cholesterol levels



Managing each of these parameters, HbA1c, blood glucose, blood pressure and
cholesterol, is important in the treatment of patients suffering from Type 2
diabetes. Reduction in HbA1c is the critical endpoint measurement in receiving
regulatory approval for a Type 2 diabetes medication. Additionally,
approximately 70% of Type 2 diabetics are prescribed antihypertensive
medication(s) to control blood pressure and prevent heart disease and stroke.
The antihypertensive and cholesterol lowering ability of DM-204 may
significantly reduce the need for such medication(s) and furthermore protect
Type 2 diabetics from heart disease and stroke complications. Administration of
DM-204 was well-tolerated and outperformed marketed Type 2 diabetes drugs
sitagliptin (Januvia(R)) and exenatide (Byetta(R)).


"These results are very encouraging and provide a strong foundation with which
to move DM-204 forward," said Dr. John Amatruda, DiaMedica's Scientific Advisory
Board member and former Senior Vice President and Franchise Head for Diabetes
and Obesity at Merck Research Laboratories.


"DM-204 has the opportunity to fundamentally change the treatment regimen for
Type 2 diabetes patients with hypertension and high cholesterol. DM-204 could
potentially become the single long-acting treatment by virtue of being a
monoclonal antibody therapy"," stated Dr. Mark Williams, Vice President, of
Research at DiaMedica. "The chronic in vivo model data shows DM-204's ability to
prevent disease progression of Type 2 diabetes and increased blood pressure." 


Summary results will be presented at the 2011 Windhover's Therapeutic Area
Partnership Conference at 3pm December 1st, 2011 at the Westin Copley Place,
Boston, MA with the full results to be published and presented in 2012.


About DiaMedica

DiaMedica is a biopharmaceutical company that has developed novel therapeutic
compounds aimed to improve the lives of patients with diabetes and other major,
medically-unmet diseases. DiaMedica's lead compound, DM-199, represents a novel
approach to treating Type 1 and Type 2 diabetes by demonstrating significant
results against three major aspects of these diseases: 1) halting the autoimmune
attack on beta cells; 2) proliferating insulin producing beta cells; and 3)
improving glucose control.


Treatment with DiaMedica's monoclonal antibody, DM-204, has demonstrated
significant improvement in glucose control, blood pressure and cholesterol
levels in in vivo models of Type 2 diabetes.


The company is listed on the TSX Venture Exchange under the trading symbol 'DMA'.

Caution Regarding Forward-Looking Information

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024